The highest frequency of mutations occurred in the KRAS gene, in the tumor biopsy (45% of cases) and plasma (43% of patients), the G12V and G13D mutations being the most frequently detected (Figure 1), followed by mutations of the PIK3CA (24% in tumor biopsy and 16% in plasma), NRAS (2% and 6%) and BRAF genes (2% and 4%), and the ES45X, Q61R/K and V600E mutations (Figure 1). This evidence concerns the gene KRAS and neoplasm.